US regulator orders makers of weight-loss drugs to carry blindness risk warning
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
The US Food and Drug Administration ordered manufacturers of GLP-1 weight-loss and obesity drugs, including Ozempic and Zepbound, to add new safety warning labels regarding a rare eye condition linked to sudden blindness and vision loss. Following these regulatory mandates, coverage of the required warnings quieted without further developments reported in the headlines.
Epilogue added 6d ago, after coverage quieted.
The brief
The U.S. Food and Drug Administration is requiring manufacturers of all GLP-1 drugs to update their prescribing information with a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding eye condition, MedPage Today reported. The warning applies to drugs including Eli Lilly's Mounjaro and Zepbound, and Novo Nordisk's Ozempic and Wegovy, according to CNN.
Cases of NAION have been documented across all currently marketed GLP-1 products, MedPage Today said. The FDA's action follows studies suggesting a potential link between GLP-1 drugs and NAION, including a 2024 JAMA Ophthalmology study involving semaglutide that prompted the agency's review. Europe's drug regulator warned about the risk 17 months ago.
In an FDA meta-analysis of randomized trials, 15 probable NAION events were identified among more than 134,000 patients. Ten cases occurred among roughly 78,000 patients treated with GLP-1 drugs, none occurred among those randomized to other glucose-lowering medications, and five occurred in placebo recipients. Incidence was 6.4 cases per 100,000 person-years among GLP-1 drug recipients compared with 3.8 cases per 100,000 person-years among patients receiving a non-GLP-1 medication or placebo.
Healthcare providers should instruct patients to immediately report sudden onset of acute, painless, decreased vision, visual field deficits, or other visual disturbances in one eye, the FDA stated in a safety communication on Monday. If NAION is suspected, patients should be promptly referred to an ophthalmologist, and clinicians should consider discontinuing the GLP-1 receptor agonist unless the benefits clearly outweigh the risk.
Novo Nordisk said it continues to believe the data do not establish a cause-and-effect relationship and remains confident in the benefit-risk profile of its GLP-1 medicines, CNN reported. Eli Lilly said it is carefully evaluating the update and will respond to the FDA promptly. Patients and clinicians can report suspected adverse reactions to the FDA's MedWatch reporting program.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.
Quick answers
What eye condition is the FDA warning about for GLP-1 weight-loss drugs?
The FDA is warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding eye condition caused by reduced blood flow to the optic disc.
Which drugs must carry the new warning?
All GLP-1 drugs must carry the warning, including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy.
What should patients do if they experience vision changes while taking a GLP-1 drug?
Patients should immediately report sudden onset of acute, painless, decreased vision, visual field deficits, or other visual disturbances in one eye to their healthcare provider.
Coverage (6)
- FDA Slaps New Safety Warning on GLP-1 Drugs MedPage Today · 8d ago
- FDA adds warning label to obesity drugs for eye condition The Seattle Times · 8d ago
- FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness NBC News · 8d ago
- FDA is requiring weight loss drug makers to add a vision loss warning Quartz · 8d ago
- US FDA orders new eye risk warnings for Ozempic, Zepbound CNN · 8d ago
- US regulator orders makers of weight-loss drugs to carry blindness risk warning Financial Times · 8d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Ozempic and Mounjaro may have a surprising effect on your brain
Coverage from five outlets reports that Ozempic and Mounjaro may affect memory and brain function, with evidence described as mixed.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.